

Cultural & Linguistic Diversity

The California legislature has passed **AB 1195** which states that as of July 1, 2006 all *AMA PRA Category 1 Credit™* CME activities that relate to patient care must include a cultural diversity/linguistics component. Specifically, the learner must be provided with relevant cultural diversity information relating to one or more of the following: age, gender, race, socio-economics, sexual orientation, religion, language, ethnicity, etc. that would impact the care of the patient.

The following bibliography of articles is provided to serve as a resource and adjunct to this activity.

1. [Exploring sociodemographic and economic factors that promote adverse drug reactions reporting by patients.](#)
Inácio P, Gomes JJ, Airaksinen M, Cavaco A.
Health Policy. 2018 Mar;122(3):263-268. doi: 10.1016/j.healthpol.2017.10.004. Epub 2017 Nov 8.
PMID: 29128200
2. [Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century.](#)
Watson S, Caster O, Rochon PA, den Ruijter H.
EClinicalMedicine. 2019 Oct 25;17:100188. doi: 10.1016/j.eclinm.2019.10.001.
eCollection 2019 Dec.
PMID: 31891132
3. [Predictors of adverse drug reactions in geriatric patients: An exploratory study among cancer patients.](#)
Sneha SG, Simhadri K, Subeesh VK, Sneha SV.
South Asian J Cancer. 2019 Apr-Jun;8(2):130-133. doi: 10.4103/sajc.sajc_218_18.
PMID: 31069198
4. [Descriptive study of adverse drug reactions in a tertiary care pediatric hospital in México from 2014 to 2017.](#)
Morales-Ríos O, Cicero-Oneto C, García-Ruiz C, Villanueva-García D, Hernández-Hernández M, Olivar-López V, Jiménez-Juárez RN, Jasso-Gutiérrez L.
PLoS One. 2020 Mar 24;15(3):e0230576. doi: 10.1371/journal.pone.0230576.
eCollection 2020.
PMID: 32208451
5. [Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.](#)
Aminkeng F, Ross CJ, Rassekh SR, Brunham LR, Sistonen J, Dube MP, Ibrahim M, Nyambo TB, Omar SA, Froment A, Bodo JM, Tishkoff S, Carleton BC, Hayden MR; Canadian Pharmacogenomics Network for Drug Safety Consortium.
Pharmacogenomics J. 2014 Apr;14(2):160-70. doi: 10.1038/tpj.2013.13. Epub 2013 Apr 16.
PMID: 23588107